نتایج جستجو برای: adalimumab

تعداد نتایج: 4006  

2015
Gerd-Rűdiger Burmester Alan J Kivitz Hartmut Kupper Udayasankar Arulmani Stefan Florentinus Sandra L Goss Suchitrita S Rathmann Roy M Fleischmann

OBJECTIVE CONCERTO was a randomised, double-blind, parallel-armed study of methotrexate (MTX) in combination with adalimumab to assess whether an increasing trend of efficacy and decreased safety exists when increasing MTX dose in patients with early rheumatoid arthritis (RA). METHODS Early, biologic and MTX-naive RA patients (N=395) were evenly randomised to open-label adalimumab (40 mg ever...

Journal: :The Journal of dermatological treatment 2011
Aslam H Anis Nick Bansback Sonia Sizto Shiraz R Gupta Mary K Willian Steve R Feldman

BACKGROUND New biologic therapies are available for moderate to severe psoriasis. OBJECTIVE To determine the most cost-effective sequence of biologic treatments. METHODS Through modeling of the clinical pathway of biologic agents, adalimumab, alefacept, efalizumab, etanercept, and infliximab, the costs and benefits (quality-adjusted life-years [QALYs]) were determined. A decision rule deter...

2016
Christina Fotiadou Efstratios Vakirlis Dimitrios Ioannides

Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease that affects the hair follicles of the aprocrine gland-bearing anatomical areas of the body. It is characterized by deep painful nodules and abscesses that rupture and contribute to the formation of sinus tracks and scarring. The management of HS is based on the assessment of disease severity and a combination of m...

2016
Stephen J Balevic C Egla Rabinovich

Uveitis refers to the presence of intraocular inflammation, and as a strict definition compromises the iris and ciliary body anteriorly and the choroid posteriorly (the uvea). Untreated, uveitis can lead to visual loss or blindness. The etiology of uveitis can include both infectious and noninfectious (usually immune-mediated) causes, the latter of which are often mediated predominantly by Th1 ...

2016
Candace L Beilman Nguyen Xuan Thanh Victoria Ung Christopher Ma Karen Wong Karen I Kroeker Thomas Lee Haili Wang Arto Ohinmaa Phil Jacobs Brendan P Halloran Richard N Fedorak

Background. Adalimumab is effective for the maintenance of remission in patients with moderate-to-severe ulcerative colitis (UC). Currently, biologic therapies are used in cases where patients fail conventional medical therapies. If biologic therapies are not available, patients often choose to remain in an unwell state rather than undergo colectomy. Objective. The aim of the study was to evalu...

Journal: :Clinical and experimental rheumatology 2016
Ignazio Olivieri Caterina Fanizza Michele Gilio Roberto Ravasio

Anti-tumour necrosis factor (TNF) agents are recommended as second-line therapy for patients with axial spondyloarthropathies. This analysis reviewed data on studies investigating the efficacy and tolerability of anti-TNF agents in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who had failed first-line non-steroidal anti-inflammatory (NSAID) treatment. Efficacy data from RCT...

Journal: :Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2015
M Galván-Banqueri M D Vega-Coca M A Castillo-Muñoz C Beltrán Calvo T Molina López

OBJECTIVE To compare the relative efficacy of infliximab, adalimumab and golimumab through adjusted indirect treatment comparisons (ITCs). METHODS An exhaustive search was performed until October 2013. Databases consulted were MEDLINE, EMBASE, the Cochrane Library, the Centre for Reviews and Dissemination and the Web of Science. Randomized control trials (RCTs) comparing the efficacy of infli...

2013
Ritesh Kohli Karim Namek

PATIENT Male, 78. FINAL DIAGNOSIS Acute lung injury due to Adalimumab. SYMPTOMS - MEDICATION Adalimumab. CLINICAL PROCEDURE Intubated and put on mechanical ventilation. SPECIALTY Pulmonology. OBJECTIVE Unusual or unexpected effect of treatment. BACKGROUND Adalimumab is a recombinant human monoclonal antibody that blocks the effects of tumor necrosis factor-alpha. Adalimumab relate...

Journal: :Arquivos de gastroenterologia 2017
Patrícia Zacharias Aderson Omar Mourão Cintra Damião Antonio Carlos Moraes Fábio Vieira Teixeira Juliano Coelho Ludvig Rodrigo Bremer Nones Rogerio Saad-Hossne Ligia Yukie Sassaki Rosemary Pereira Lino da Silva Luiza Facchin Marcia Olandoski Paulo Gustavo Kotze

BACKGROUND Adalimumab is a monoclonal antibody, tumor necrosis factor-alpha (TNFα) inhibitor that has efficacy for inducing and maintaining remission in moderate-to-severe ulcerative colitis. Real world studies with adalimumab in Latin American ulcerative colitis patients are scarce. OBJECTIVE To assess the clinical remission rates in induction and maintenance with adalimumab therapy in ulcer...

2013
Alireza Hedayatfar Masoud Soheilian

PURPOSE To report a case of recurrent idiopathic frosted branch angiitis (FBA) successfully treated with adalimumab. CASE REPORT A 14-year-old otherwise healthy boy was referred to the uveitis clinic for bilateral panuveitis with diffuse retinal vascular sheathing and severe macular edema. Extensive work-up including aqueous sampling for detection of viral causes was inconclusive. Two years a...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید